Isogenica inks licensing deal with Aro Biotherapeutics for development of scaffold molecules

handshake over a desk with computers and someone taking notes
Isogenica has inked a licensing deal with Aro Biotherapeutics to use its in vitro polypeptide display systems for the development of Aro’s scaffold molecule technology. (raw pixel)

Isogenica has inked a licensing deal with Aro Biotherapeutics to use its in vitro polypeptide display systems for the development of Aro’s scaffold molecule technology.

The Philadelphia-based Aro is developing Centyrins, a class of scaffold molecules that can bind to target proteins. The company hopes the platform will address unmet needs through the targeted delivery of a variety of drug payloads to specific cells or tissues.

Aro was co-founded earlier this year by two former Johnson & Johnson leaders, Susan Dillon and Karyn O’Neil.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

Under terms of the agreement, Isogenica will get an upfront fee from Aro and annual license payments. Isogenica will be eligible for milestone money if products advance into development.

Isogenica will provide Centyrin discovery services for specific targets nominated by Aro.

“Isogenica continues to attract leading-edge partners, giving them access to our novel CIS Display technology and supporting them in advancing their own discovery programs,” Adam Collier, Isogenica’s director of commercial development, said in a statement. “Aro is an exciting new company with a unique technology and we look forward to our partnership with them.”